Lattice Biologics Ltd., a biotech company, develops, manufactures, and markets biologics products for use in the field of bone regeneration in dental, spine, and general orthopedic indications worldwide. It develops acellular demineralized bone scaffold, a human cortical bone demineralized that are used in various applications in orthopedic, neurological, trauma, oral/maxillofacial, and reconstruc...
Lattice Biologics reported revenue of $2.46 million for fiscal year 2020, up 12.6% from fiscal year 2019, and net income of -$1.48 million. In Q3 2021 (the quarter ended June 30, 2021) revenue was $0, down 100.0% from a year before. Its market capitalization was $16,545 as of October 8, 2026.
Figures from company filings and market data; latest fiscal year ended September 30, 2020; market data as of October 8, 2026.
No profile data available.